Fortis Therapeutics gathers $40m Series A

Fortis Therapeutics, Inc., an immuno-oncology biotech company, has raised $40 million in Series A financing.

Fortis Therapeutics, Inc., an immuno-oncology biotech company, has raised $40 million in Series A financing. The investors included Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners and Vivo Capital.

Source: Press Release